论文部分内容阅读
目的观察替吉奥联合奥沙利铂治疗晚期结直肠癌的疗效和毒副作用。方法 15例经病理组织学确诊的IV期结直肠癌患者,其中肝转移5例,肺转移3例,骨转移3例,盆腔转移4例;其中结肠癌8例,直肠癌7例,接受奥沙利铂130mg/m2d1,替吉奥40-60mg/m2,每天2次。d1-d14每21天重复,参照WHO标准观察和评价近期客观疗效,至少2周期评价疗效。结果 15例患者均可评价客观疗效和药物毒副反应,获得CR1例,PR5例,SD5例,PD4例,即有效率(CR+PR)10%,病症控制率(DCR)71.4%,主要不良反应为胃肠道反应及骨髓抑制。结论替吉奥和奥沙利铂联合应用治疗晚期结直肠癌,具有良好疗效,毒性低,可耐受安全性高,值得临床上进一步应用观察。
Objective To observe the efficacy and side effects of tegafur and oxaliplatin in the treatment of advanced colorectal cancer. Methods Fifteen cases of stage IV colorectal cancer patients diagnosed by histopathology included 5 cases of hepatic metastases, 3 cases of pulmonary metastases, 3 cases of bone metastases, and 4 cases of pelvic metastasis; 8 cases of colon cancer, 7 cases of rectal cancer, and 5 cases of rectal cancer. Saliplatin 130 mg/m2d1 and Teggio 40-60 mg/m2 twice daily. D1-d14 is repeated every 21 days. Refer to the WHO standard for observation and evaluation of recent objective effects, and assess efficacy with at least 2 cycles. Results The objective efficacy and drug toxicity were evaluated in 15 patients, and 1 CR, 5 PR, 5 SD, and 4 PD were obtained. The effective rate (CR+PR) was 10%, and the disease control rate (DCR) was 71.4%. The reaction was gastrointestinal reactions and myelosuppression. Conclusion The combination of tegafur and oxaliplatin in the treatment of advanced colorectal cancer has good curative effect, low toxicity, high tolerance to safety, and worthy of further clinical application.